The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease (PR-ILD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01055730 |
|
Recruitment Status :
Completed
First Posted : January 26, 2010
Last Update Posted : November 21, 2013
|
Sponsor:
University of California, San Francisco
Information provided by (Responsible Party):
University of California, San Francisco
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to determine if pulmonary rehabilitation has any effect on breathlessness, quality of life, physical function and depression in persons with interstitial lung disease.
| Condition or disease | Intervention/treatment |
|---|---|
| Interstitial Lung Disease | Other: Pulmonary rehabilitation |
| Study Type : | Observational |
| Actual Enrollment : | 54 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study |
| Study Start Date : | February 2010 |
| Actual Primary Completion Date : | January 2013 |
| Actual Study Completion Date : | January 2013 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Pulmonary alveolar microlithiasis
| Group/Cohort | Intervention/treatment |
|---|---|
| Pulmonary rehabilitation |
Other: Pulmonary rehabilitation
Structured education and supervised exercise program, lasting between 6 and 9 weeks. |
Primary Outcome Measures :
- 6-minute walk distance [ Time Frame: Immediately following completion of pulmonary rehabilitation and 6 months following the start of pulmonary rehabilitation ]
- Quality of life [ Time Frame: Immediately following completion of pulmonary rehabilitation and 6 months following the start of pulmonary rehabilitation ]
Secondary Outcome Measures :
- Dyspnea [ Time Frame: Immediately following completion of pulmonary rehabilitation and 6 months following the start of pulmonary rehabilitation ]
- Depression [ Time Frame: Immediately following completion of pulmonary rehabilitation and 6 months following the start of pulmonary rehabilitation ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Any patient with interstitial lung disease who is referred to a participating pulmonary rehabilitation program. These patients typically have exercise limitation and dyspnea, but still possess the ability to perform some exercise.
Criteria
Inclusion Criteria:
- Adults (> 18 years old) with a diagnosis of ILD who are referred to a participating PR program
Exclusion Criteria:
- Inability to provide informed consent
- Inability to read and write English
- Any other medical condition that significantly limits the subject's ability to perform the functional measures
- Emphysema / Chronic bronchitis (FEV1 / FVC ratio < 60%)
- Previous pulmonary rehabilitation
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01055730
Locations
| United States, California | |
| John Muir Health | |
| Concord, California, United States, 94520 | |
| Seton Pulmonary & Cardiac Rehabilitation | |
| Daly City, California, United States, 94015 | |
| United States, Connecticut | |
| Yale University School of Medicine | |
| New Haven, Connecticut, United States, 06520-8057 | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27710 | |
| United States, Virginia | |
| Inova Fairfax Hospital | |
| Falls Church, Virginia, United States, 22042 | |
| Canada, British Columbia | |
| University of British Columbia | |
| Vancouver, British Columbia, Canada, V6Z 1Y6 | |
Sponsors and Collaborators
University of California, San Francisco
Investigators
| Principal Investigator: | Harold R Collard, MD | University of California, San Francisco | |
| Principal Investigator: | Christopher J Ryerson, MD | University of California, San Francisco | |
| Principal Investigator: | Chris Garvey, FNP | Seton Pulmonary & Cardiac Rehabilitation |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT01055730 History of Changes |
| Other Study ID Numbers: |
PR-ILD |
| First Posted: | January 26, 2010 Key Record Dates |
| Last Update Posted: | November 21, 2013 |
| Last Verified: | November 2013 |
Keywords provided by University of California, San Francisco:
|
Pulmonary rehabilitation Exercise therapy Interstitial lung disease Pulmonary fibrosis |
Mobility limitation Dyspnea Mental health |
Additional relevant MeSH terms:
|
Lung Diseases Lung Diseases, Interstitial Respiratory Tract Diseases |